⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600328 | 1.00 | — | — | |
| SCHEMBL29446 | 1.00 | — | — | |
| Acetic Acid SCHEMBL8429276 | 0.94 | HCAR2 (0.55) | — | |
| SCHEMBL18824999 | 0.92 | HCAR2 (0.64) | — | |
| Acrylic Acid SCHEMBL11798847 | 0.89 | HCAR2 (0.55) | — | |
| Acrylamide SCHEMBL11422172 | 0.87 | HCAR2 (0.44) | — | |
| SCHEMBL17135006 | 0.86 | HCAR2 (0.42) | — | |
| SCHEMBL3207425 | 0.84 | ATM (0.46) | — | |
| SCHEMBL828236 | 0.84 | HCAR2 (0.39) | — | |
| Diethyl Maleate SCHEMBL28692587 | 0.83 | HCAR2 (0.76) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088823-A1 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11319289-B2 | 5-hydroxy pyridine-based compound for use as P2X1 and P2X3 receptor antagonist and pharmaceutical composition comprising same | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-05-03 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-1997031002-A9 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997031002-A1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| EP-0785938-A1 | FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5616724-A | FOR POTENTIATION OF HUMAN INTERFERON-GAMMA; IMMUNOLOGY | CEPHALON, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5594009-A | KINASE INHIBITORS, TROPHIC FACTOR-INDUCED ACTIVITY ENHANCEMENT, CELL SURVIVAL | CEPHALON, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5591855-A | KINASE INHIBITORS, TROPHIC FACTOR-INDUCED ACTIVITY ENHANCEMENT, CELL SURVIVAL | CEPHALON, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5475110-A | Treating nervous system disorders and inflammation, inhibiting protein and tyrosine kinases, inhibiting cell growth | CEPHALON, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-4335054-A | Process for the preparation of alkenylbenzenecarboxylic acid derivatives and alkenylnaphthalenecarboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1982-06-15 | — | — | US | disclosed |
| US-4028201-A | Electrolytic monocarboxylation of activated olefins | MONSANTO COMPANY (US) | 1977-06-07 | — | — | US | disclosed |
| US-4013524-A | Electrolytic carboxylation and dimerization of olefins | MONSANTO COMPANY (US) | 1977-03-22 | — | — | US | disclosed |